Leukapheresis Market Size

Leukapheresis Market Analysis

The Leukapheresis Market size is estimated at USD 69.77 billion in 2024, and is expected to reach USD 98.55 billion by 2029, growing at a CAGR of 7.15% during the forecast period (2024-2029).

• COVID-19 impacted the leukapheresis market due to disruption in non-essential procedures like leukapheresis, reduced availability of donors, and delayed clinical trials in order to increase focus on COVID-19-related research. For instance, as per an article published in January 2022 in BioMed Research Journal, blood donation dropped by 40% to 67% during the initial year of the pandemic in regions where travel restrictions were in place.
• Hence, owing to the factors mentioned above, COVID-19 had a significant impact on the studied market. However, the market is re-gaining its pre-pandemic nature regarding the demand for leukapheresis procedures, which in turn is expected to boost the utilization of leukapheresis devices. Furthermore, due to the increasing prevalence of leukemia and the growing demand for leukopaks in clinical research activities, the market is believed to witness significant growth over the forecast period.
• The rising incidence of leukemia disorders is expected to boost the demand by increasing the usage rates of leukapheresis machines and kits. For instance, according to the Leukemia Foundation 2022 update, an expected 19,403 Australians were diagnosed with a blood cancer such as leukemia, lymphoma, and myeloma in 2022. This was equivalent to 53 people per day or one person every 27 minutes. The same source stated that 135,000 people were living with blood cancer in Australia in 2022, and more than 275,000 Australians are expected to be living with blood cancer by 2035.
• Additionally, as per the report published by Blood Cancer UK in August 2022, blood cancer is the fifth most common cancer in the United Kingdom, with over 41,000 people being diagnosed with it every year. Hence, the rising burden of leukemia and blood cancer is creating the need for advanced therapeutics based on leukapheresis for treatment, which is expected to drive the market's growth over the forecast period.
• Furthermore, an article published in July 2021 in the International Journal of General Medicine stated that leukapheresis has emerged as one of the most essential adjuvant therapies to treat hyperleukocytosis, particularly in patients who were not unsuitable to cytoreduce with Ara-C or hydroxyurea. Leukapheresis is frequently used to treat a variety of illnesses. It is also employed for diagnostic purposes because it can boost the production of circulating tumor cells. The high number of research studies on leukapheresis is expected to propel the market growth during the forecast period.
• The rising company initiatives, such as product launches and technological advancements, are also contributing to growth in the leukapheresis market. For instance, in July 2021, Terumo Blood and Cell Technologies announced a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside. The company has expanded the functionality of Spectra Optia. The UVA PIT System ECP can now be performed using these devices as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.
• Similarly, in June 2022, Terumo reported that the United States National Health Service (NHS) England acquired the Terumo's Spectra Optia Apheresis System to treat sickle cell disease. Such developments to increase the offerings of leukapheresis for healthcare professionals are expected to propel the market growth.
• Therefore, owing to the aforementioned factors, such as the high burden of blood cancer and rising strategic initiatives by market players for technological advancements and launches in leukapheresis, the studied market is anticipated to witness growth over the analysis period. However, the high cost of therapeutic leukapheresis and stringent regulatory issues for donor recruitment are expected to hinder the growth of the market during the forecast period.